Starling Oncology
STLN
36 hedge funds and large institutions have $111M invested in Starling Oncology in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
24% more funds holding
Funds holding: 29 → 36 (+7)
1.1% more ownership
Funds ownership: 28.79% → 29.89% (+1.1%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
30% less capital invested
Capital invested by funds: $159M → $111M (-$48.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.52M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.37M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.22M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.2M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$917K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$4.94M |
| 2 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$1.9M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$759K |
| 4 |
EAM
Empery Asset Management
New York
|
-$504K |
| 5 |
TM
Triatomic Management
Palo Alto,
California
|
-$455K |
STLN Hedge Fund Activity: Q2 2022 in Review
36 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q2 2022, worth a combined $111M — down 30% from $159M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new STLN positions and 9 closed out — a net gain of 7 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $5.52M. The largest seller was Redmile Group, cutting an estimated $4.94M.
- 36 institutional investors held Starling Oncology (STLN) as of Q2 2022, up from 29 in Q1 2022.
- Funds reported $111M of Starling Oncology stock for Q2 2022, down 30% quarter-over-quarter.
- 16 funds opened new Starling Oncology positions in Q2 2022 and 9 closed out, a net change of +7 holders.
- The largest Starling Oncology buyer in Q2 2022 was BlackRock, an estimated $5.52M added.
- The largest Starling Oncology seller in Q2 2022 was Redmile Group, an estimated $4.94M sold.
Based on aggregated 13F filings for Q2 2022.